Pub Date : 2019-10-01DOI: 10.1097/FAD.0000000000000043
Daniel R Burrage
Many drugs have the potential to cause intracerebral haemorrhage. The mechanisms that underlie this association include elevation of blood pressure and increasing bleeding tendency. The consequences of intracerebral haemorrhage can be devastating for the individual, so careful risk assessment prior to drug initiation and close monitoring during treatment should be enacted when using medicines with an established association with haemorrhagic stroke.
{"title":"Drug causes of intracerebral haemorrhage","authors":"Daniel R Burrage","doi":"10.1097/FAD.0000000000000043","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000043","url":null,"abstract":"Many drugs have the potential to cause intracerebral haemorrhage. The mechanisms that underlie this association include elevation of blood pressure and increasing bleeding tendency. The consequences of intracerebral haemorrhage can be devastating for the individual, so careful risk assessment prior to drug initiation and close monitoring during treatment should be enacted when using medicines with an established association with haemorrhagic stroke.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49550049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-01DOI: 10.1097/FAD.0000000000000042
H. Horwitz, T. Christoffersen
Henrik Horwitz & Thea Christof Department of Clinical Pharmacology, Bis fersen pebjerg and Frederiksberg Hospital, København NV and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Correspondence to Henrik Horwitz, MD, PhD, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark. Private address: Pile Alle 5b st. tv., 2000 Frederiksberg, Denmark. E-mail: henrik_horwitz@hotmail.com, henrik.horwitz@regionh.dk
Henrik Horwitz和Thea Christof临床药理学系，Bis fersen pebjerg和Frederiksberg医院，København NV和哥本哈根大学临床医学系，丹麦哥本哈根。Henrik Horwitz，医学博士，博士，临床药理学系，Bispebjerg和Frederiksberg医院，哥本哈根大学，丹麦。私人地址：Pile Alle 5b st.tv.2000 Frederiksberg，丹麦。电子邮件：henrik_horwitz@hotmail.com，henrik.horwitz@regionh.dk
{"title":"A review on the health hazards of anabolic steroids","authors":"H. Horwitz, T. Christoffersen","doi":"10.1097/FAD.0000000000000042","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000042","url":null,"abstract":"Henrik Horwitz & Thea Christof Department of Clinical Pharmacology, Bis fersen pebjerg and Frederiksberg Hospital, København NV and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Correspondence to Henrik Horwitz, MD, PhD, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark. Private address: Pile Alle 5b st. tv., 2000 Frederiksberg, Denmark. E-mail: henrik_horwitz@hotmail.com, henrik.horwitz@regionh.dk","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000042","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46365585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.1097/FAD.0000000000000041
Daniel R Burrage
There is a wide range of drugs with the potential to cause ischaemic stroke. Whilst the absolute risk of stroke with commonly used drugs is low, a patient’s background risk of stroke can increase their chance of stroke in combination with a particular drug. Careful decision-making is required when initiating and continuing treatment to ensure the risk-benefit profile of a drug is weighed appropriately on an individual patient basis.
{"title":"Drug causes of ischaemic stroke","authors":"Daniel R Burrage","doi":"10.1097/FAD.0000000000000041","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000041","url":null,"abstract":"There is a wide range of drugs with the potential to cause ischaemic stroke. Whilst the absolute risk of stroke with commonly used drugs is low, a patient’s background risk of stroke can increase their chance of stroke in combination with a particular drug. Careful decision-making is required when initiating and continuing treatment to ensure the risk-benefit profile of a drug is weighed appropriately on an individual patient basis.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48617174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-01DOI: 10.1097/FAD.0000000000000040
W. Hutton, M. Pucci
Summary Acquired methaemoglobinaemia can be caused by the oxidising effect of a number of different drugs. Prescribed drugs that cause methaemoglobinaemia include local anaesthetics, dapsone, sulphonamides and primaquine. Recreational drugs such as amyl and isobutyl nitrite (‘poppers’) and adulterants in cocaine are also well known to cause methaemoglobinaemia. Low concentrations of methaemoglobin do not require treatment, but higher concentrations can be fatal. When indicated, methylthioninium chloride is the treatment of choice. More complicated cases should be discussed with a local poisons centre.
{"title":"Drug induced methaemoglobinaemia","authors":"W. Hutton, M. Pucci","doi":"10.1097/FAD.0000000000000040","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000040","url":null,"abstract":"Summary Acquired methaemoglobinaemia can be caused by the oxidising effect of a number of different drugs. Prescribed drugs that cause methaemoglobinaemia include local anaesthetics, dapsone, sulphonamides and primaquine. Recreational drugs such as amyl and isobutyl nitrite (‘poppers’) and adulterants in cocaine are also well known to cause methaemoglobinaemia. Low concentrations of methaemoglobin do not require treatment, but higher concentrations can be fatal. When indicated, methylthioninium chloride is the treatment of choice. More complicated cases should be discussed with a local poisons centre.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"315 1","pages":"1219–1222"},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000040","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42970773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-02-01DOI: 10.1097/FAD.0000000000000038
Laurence A. Gray, P. Routledge
Summary In this journal in 1976, Professor Duncan Vere suggested that some adverse drug reactions could behave as “masqueraders”, sometimes evading detection for a considerable time after a medicine was introduced into clinical practice. Using contemporary examples, we illustrate why we believe the five main reasons he cited for adverse drug reactions masquerading in this manner remain just as relevant today. Although newer methods of investigation are increasingly contributing to improved surveillance, individual case reports and spontaneous reporting systems for suspected adverse drug reactions remain a cornerstone of pharmacovigilance and should continue during the whole of the time that medicines continue to be used therapeutically.
{"title":"Adverse Drug Reactions, still masquerading after all these years?","authors":"Laurence A. Gray, P. Routledge","doi":"10.1097/FAD.0000000000000038","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000038","url":null,"abstract":"Summary In this journal in 1976, Professor Duncan Vere suggested that some adverse drug reactions could behave as “masqueraders”, sometimes evading detection for a considerable time after a medicine was introduced into clinical practice. Using contemporary examples, we illustrate why we believe the five main reasons he cited for adverse drug reactions masquerading in this manner remain just as relevant today. Although newer methods of investigation are increasingly contributing to improved surveillance, individual case reports and spontaneous reporting systems for suspected adverse drug reactions remain a cornerstone of pharmacovigilance and should continue during the whole of the time that medicines continue to be used therapeutically.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"314 1","pages":"1215–1218"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000038","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45383998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.1097/01.fad.0000550514.24091.58
{"title":"Drug Index 2018","authors":"","doi":"10.1097/01.fad.0000550514.24091.58","DOIUrl":"https://doi.org/10.1097/01.fad.0000550514.24091.58","url":null,"abstract":"","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.fad.0000550514.24091.58","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46571866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-01DOI: 10.1097/FAD.0000000000000037
Maija Bruun Haastrup, D. Henriksen, M. Christensen
Summary Sialorrhoea is a common adverse effect of a range of medicines, primarily clozapine. At least a third of patients treated with clozapine suffer from sialorrhoea, and the consequences of this can be socially stigmatising and lead to non-adherence. The treatment options are limited and primarily centered around muscarinic antagonism. We suggest non-pharmacological interventions followed by locally applied atropine or glycopyrrolate. If systemic treatment is necessary, amisulpride, benztropine, or terazosin may be attempted.
{"title":"Drug-induced Sialorrhoea","authors":"Maija Bruun Haastrup, D. Henriksen, M. Christensen","doi":"10.1097/FAD.0000000000000037","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000037","url":null,"abstract":"Summary Sialorrhoea is a common adverse effect of a range of medicines, primarily clozapine. At least a third of patients treated with clozapine suffer from sialorrhoea, and the consequences of this can be socially stigmatising and lead to non-adherence. The treatment options are limited and primarily centered around muscarinic antagonism. We suggest non-pharmacological interventions followed by locally applied atropine or glycopyrrolate. If systemic treatment is necessary, amisulpride, benztropine, or terazosin may be attempted.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"34 22","pages":"1211–1214"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41309351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-10-01DOI: 10.1097/fad.0000000000000036
U. Thatte, Nayan Chaudhari, N. Gogtay
Unlike developed nations most of whom put into place systems of pharmacovigilance in the early 1960s following the thalidomide disaster, India’s Pharmacovigilance Program formally began only in the mid-1980s. After several unsuccessful attempts, a robust program was put in place by the Central Drugs Standard Control Organization in 2010 called the Pharmacovigilance Program of India. Today, this is a stable system with the Indian regulator at the helm, a formal legislation in place to support the program and a National Coordinating Center located at the Indian Pharmacopoeia Commission. In the 8 years since its resurrection, the activities have expanded by leaps and bounds. There are 250 adverse reactions monitoring centers throughout the country and India contributes 1.7% of Individual Case Safety Reports to the Uppsala Monitoring Center’s database. The WHO, recognizing India’s concerted efforts in the area of pharmacovigilance, established its first WHO Collaborating Centre for Pharmacovigilance in Public Health Programs and Regulatory Services at the National Coordinating Center. The proposed expansion of the program in the coming years will further strengthen the cause of medicines safety in the country in line with the WHO’s Third Global Patient Safety Challenge of Medication without Harm.
{"title":"Pharmacovigilance Program of India: history, evolution and current status","authors":"U. Thatte, Nayan Chaudhari, N. Gogtay","doi":"10.1097/fad.0000000000000036","DOIUrl":"https://doi.org/10.1097/fad.0000000000000036","url":null,"abstract":"Unlike developed nations most of whom put into place systems of pharmacovigilance in the early 1960s following the thalidomide disaster, India’s Pharmacovigilance Program formally began only in the mid-1980s. After several unsuccessful attempts, a robust program was put in place by the Central Drugs Standard Control Organization in 2010 called the Pharmacovigilance Program of India. Today, this is a stable system with the Indian regulator at the helm, a formal legislation in place to support the program and a National Coordinating Center located at the Indian Pharmacopoeia Commission. In the 8 years since its resurrection, the activities have expanded by leaps and bounds. There are 250 adverse reactions monitoring centers throughout the country and India contributes 1.7% of Individual Case Safety Reports to the Uppsala Monitoring Center’s database. The WHO, recognizing India’s concerted efforts in the area of pharmacovigilance, established its first WHO Collaborating Centre for Pharmacovigilance in Public Health Programs and Regulatory Services at the National Coordinating Center. The proposed expansion of the program in the coming years will further strengthen the cause of medicines safety in the country in line with the WHO’s Third Global Patient Safety Challenge of Medication without Harm.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/fad.0000000000000036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45849842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-01DOI: 10.1097/FAD.0000000000000035
K. Dalhoff, J. Andersen, E. Jimenez‐Solem, K. Dalhoff
Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg and Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Correspondence to Kim Dalhoff, MD, DMSc, FEAPCCT, Professor of Clinical Pharmacology (Clinical Toxicology), Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Frederiksberg, 2400 Copenhagen, Denmark. Tel: +45 3863 5101; Mobile: (45) 2825 4783; e-mail: kim.peder.dalhoff@regionh.dk
{"title":"A new beginning: Adverse drug reaction manager a way of increasing the number of spontaneous reporting","authors":"K. Dalhoff, J. Andersen, E. Jimenez‐Solem, K. Dalhoff","doi":"10.1097/FAD.0000000000000035","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000035","url":null,"abstract":"Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg and Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark Correspondence to Kim Dalhoff, MD, DMSc, FEAPCCT, Professor of Clinical Pharmacology (Clinical Toxicology), Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital, Frederiksberg, 2400 Copenhagen, Denmark. Tel: +45 3863 5101; Mobile: (45) 2825 4783; e-mail: kim.peder.dalhoff@regionh.dk","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"311 1","pages":"1203–1206"},"PeriodicalIF":0.0,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45414373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1097/FAD.0000000000000034
R. Ferner, C. Anton
Summary After 20 years, Robin Ferner and Christopher Anton, who took on responsibility for the Adverse Drug Reaction Bulletin from its founder Professor Dai Davies, are handing over responsibility to Professor Kim Dalhoff and his colleague Dr Jon Andersen in Copenhagen. They take the opportunity to review some interesting, important, or unusual clinical aspects of adverse drug reactions encountered over the last twenty years.
{"title":"Twenty years of adverse drug reactions: a look back – part 2","authors":"R. Ferner, C. Anton","doi":"10.1097/FAD.0000000000000034","DOIUrl":"https://doi.org/10.1097/FAD.0000000000000034","url":null,"abstract":"Summary After 20 years, Robin Ferner and Christopher Anton, who took on responsibility for the Adverse Drug Reaction Bulletin from its founder Professor Dai Davies, are handing over responsibility to Professor Kim Dalhoff and his colleague Dr Jon Andersen in Copenhagen. They take the opportunity to review some interesting, important, or unusual clinical aspects of adverse drug reactions encountered over the last twenty years.","PeriodicalId":39261,"journal":{"name":"Adverse Drug Reaction Bulletin","volume":"310 1","pages":"1199–1202"},"PeriodicalIF":0.0,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/FAD.0000000000000034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43489778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：